Warrior Met Coal Inc. (HCC)
Warrior Met Coal (HCC) Tops Q3 Earnings and Revenue Estimates
Warrior Met Coal (HCC) came out with quarterly earnings of $0.7 per share, beating the Zacks Consensus Estimate of a loss of $0.2 per share. This compares to earnings of $0.8 per share a year ago.
Earnings Preview: Warrior Met Coal (HCC) Q3 Earnings Expected to Decline
Warrior Met Coal (HCC) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Warrior Met Coal: Above Expectations In Q2 And Likely Higher Coal Prices Ahead
Warrior Met Coal boasts strong margins, low transport costs, and a robust balance sheet, outperforming peers despite weak coking coal prices. Q2 2025 results beat expectations with higher EBITDA and improved cash margins, aided by cost reductions and increased sales guidance. Blue Creek project is ahead of schedule, set to boost production and EBITDA by 50-60%, supporting future growth.
Warrior Met Coal, Inc. (HCC) Q2 2025 Earnings Call Transcript
Warrior Met Coal, Inc. (NYSE:HCC ) Q2 2025 Earnings Conference Call August 6, 2025 4:30 PM ET Company Participants Brian M. Chopin - Senior VP, Chief Accounting Officer & Controller Dale W.
Warrior Met Coal (HCC) Tops Q2 Earnings and Revenue Estimates
Warrior Met Coal (HCC) came out with quarterly earnings of $0.11 per share, beating the Zacks Consensus Estimate of a loss of $0.28 per share. This compares to earnings of $1.35 per share a year ago.
Analysts Estimate Warrior Met Coal (HCC) to Report a Decline in Earnings: What to Look Out for
Warrior Met Coal (HCC) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
US Met Coal Stocks: Warrior Met Coal Better Than Alpha Metallurgical Resources, But I Rate Both A Hold
Warrior Met Coal is slightly more attractive than Alpha Metallurgical Resources due to higher gross margins and average coal quality, but both remain fundamentally sound. Until metallurgical coal prices bottom and trade policy uncertainties dissipate, a Hold rating for both HCC and AMR seems justified. While valuations for both companies are historically high, HCC is currently relatively cheaper than AMR.
Warrior Met Coal, Inc. (HCC) Q1 2025 Earnings Call Transcript
Warrior Met Coal, Inc. (NYSE:HCC ) Q1 2025 Earnings Conference Call April 30, 2025 4:30 PM ET Company Participants Brian Chopin - Chief Accounting Officer and Controller Walter Scheller - Chief Executive Officer Dale Boyles - Chief Financial Officer Conference Call Participants Katja Jancic - BMO Capital Markets Nick Giles - B. Riley Securities George Eady - UBS Nathan Martin - The Benchmark Company Operator Good afternoon, my name is Dhawan, and I will be your conference operator today.
Warrior Met Coal (HCC) Reports Q1 Loss, Tops Revenue Estimates
Warrior Met Coal (HCC) came out with a quarterly loss of $0.16 per share versus the Zacks Consensus Estimate of a loss of $0.05. This compares to earnings of $2.63 per share a year ago.
Analysts Estimate Warrior Met Coal (HCC) to Report a Decline in Earnings: What to Look Out for
Warrior Met Coal (HCC) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Warrior Met Coal: Low-Cost Producer With Upside
Warrior Met Coal, Inc. is well-positioned to weather current low coal prices due to its low-cost production and strong balance sheet, with Blue Creek set to enhance margins and production. Despite current oversupply and weak market conditions, long-term demand for metallurgical coal is expected to rise, driven by emerging markets like India and the green energy transition. The Blue Creek project, on time and on budget, will significantly boost HCC's production and margins, making it a valuable long-term investment below $50/share.
EC Approves Bristol Myers' Opdivo Plus Yervoy for First-Line HCC
The EC approves BMY's combination of Opdivo and Yervoy for the first-line treatment of adult patients with unresectable or advanced hepatocellular carcinoma.
